Epclusa
Named-patient access overview. Epclusa is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Epclusa (sofosbuvir 400 mg / velpatasvir 100 mg) is an oral fixed-dose pangenotypic direct-acting antiviral combining a nucleotide NS5B polymerase inhibitor with an NS5A inhibitor, developed by Gilead Sciences and first approved by the US Food and Drug Administration in June 2016. It is indicated for the treatment of chronic hepatitis C virus infection in adults and paediatric patients 3 years and older, across all six major HCV genotypes, with or without compensated cirrhosis, and in combination with ribavirin for patients with decompensated cirrhosis. Dosing is one tablet taken orally once daily for 12 weeks, prescribed and monitored by a hepatologist, infectious disease specialist, or gastroenterologist.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Epclusa
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Epclusa is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Epclusa in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Epclusa
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.